VIDEO: Following up IMbrave050 study will be important in hepatocellular carcinoma
In this video, Thomas Marron, MD, PhD, discussed results from the phase 3 IMbrave050 study, presented at American Association for Cancer Research Annual Meeting.
Marron, an associate professor of medicine at Icahn School of Medicine at Mount Sinai, highlighted the study, which found increased recurrence-free survival of patients with hepatocellular carcinoma treated with adjuvant therapy with atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech), a benefit that was especially significant in comparison with sorafenib (Nexavar, Bayer), although the picture is still incomplete.
“Following up this overall survival data is going to be super important, in particular because in this trial patients that did progress were able to receive standard therapy in the advanced setting,” Marron said.
Collapse
Read more about